A-Alpha Bio Partners with Lawrence Livermore National Laboratory to Accelerate AI-based Antibody Design

We are excited to be part of the pioneering DeNOVO Initiative, aimed at revolutionizing antibody development and accelerating biologics discovery.

In collaboration with Lawrence Livermore National Laboratory and other world-leading institutions, the 3-year project will apply high-performance computing and artificial intelligence approaches to generate effective antibody designs that could neutralize future biothreats.

The high-throughput protein interaction data generated by A-Alpha Bio’s AlphaSeq platform will help our partners to train and validate ML models that predict antibody-antigen binding.

The collaboration brings together talented researchers from 5 institutions:

• A-Alpha Bio
• Institute for Protein Design, University of Washington
• Lawrence Livermore National Laboratory
• Los Alamos National Laboratory
• University of California, San Francisco

We look forward to working together to transform in silico antibody designs into high-impact therapeutics.

To learn more, see today’s press release here.

(Image credit: Dan Herchek/LLNL).